Nicox appoints Joseph Boyd as Director, Medical Development and Advocacy in the United States
November 10, 2013
Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX) today announces the appointment of Joseph Boyd as Director, Medical Development and Advocacy, in its US subsidiary Nicox Inc. Mr. Boyd will be responsible for the Company’s educational efforts among Key Opinion Leaders, medical societies and advocacy groups in the US ophthalmic space. This appointment is part of the Company’s efforts to strengthen its US operations to support the commercialization of AdenoPlus® and the planned launch of the Dry Eye Panel for Sjögren’s Syndrome by the end of 2013. Nicox Inc’s team will attend the 2013 Annual Meeting of the American Academy of Ophthalmology (AAO), from November 16 to 18, 2013 in New Orleans, LA (booth number 4719).
Mr. Boyd has over 17 years of experience in the pharmaceutical and medical device industry. Prior to joining Nicox, Mr. Boyd was Director, Compliance Operations, at Astellas US, LLC, where he managed the Operations function for the Corporate Compliance Department in the Americas and had previously served as Director, Marketing Operations. Prior to Astellas, he was Director, Ophthalmic Medical Development at Inspire Pharmaceuticals, Inc., a subsidiary of Merck, where he played a key role in building the Medical Affairs department; focused extensively on medical education, Key Opinion Leader advocacy and competitive intelligence. In addition, Mr. Boyd previously worked for Alcon Laboratories, Boston Scientific, and Muro Pharmaceuticals, Inc.